Datasheet

Biological Description

Specificity	E2F-1 Antibody [N6L18] detects endogenous levels of total E2F-1 protein.
Background	E2F1, also known as E2F transcription factor 1, belongs to the E2F family of transcription factors that are central regulators of cell cycle progression and DNA synthesis. E2F1 contains a DNA-binding domain, a transcriptional activation domain, and a dimerization domain that allows binding to DP1/DP2 partners forming transcriptionally active heterodimers. The E2F1 protein specifically recognizes E2F-responsive elements in promoter regions of target genes essential for the G1/S transition. Through its interaction with the retinoblastoma (pRB) tumor suppressor, E2F1 activity is tightly controlled, as pRB binding represses E2F1-mediated transcription until phosphorylation releases E2F1 during the late G1 phase. E2F1 upregulates genes required for DNA replication, including those encoding cyclins, DNA polymerases, and dihydrofolate reductase. E2F1 exerts a dual role in cell fate by promoting apoptosis under stress conditions through both p53-dependent and independent mechanisms, involving transcriptional activation of pro-apoptotic genes such as APAF-1, p73, and caspases. E2F1 is phosphorylated and stabilized by ATM/ATR kinases in response to DNA damage, linking genotoxic stress signaling to apoptosis. Elevated E2F1 expression has been correlated with oncogenic transformation in multiple cancers, where its deregulation promotes uncontrolled proliferation and genomic instability. Moreover, aberrant E2F1 activity has been implicated in neuronal apoptosis, contributing to neurodegenerative disorders.

Specificity

E2F-1 Antibody [N6L18] detects endogenous levels of total E2F-1 protein.

Background

E2F1, also known as E2F transcription factor 1, belongs to the E2F family of transcription factors that are central regulators of cell cycle progression and DNA synthesis. E2F1 contains a DNA-binding domain, a transcriptional activation domain, and a dimerization domain that allows binding to DP1/DP2 partners forming transcriptionally active heterodimers. The E2F1 protein specifically recognizes E2F-responsive elements in promoter regions of target genes essential for the G1/S transition. Through its interaction with the retinoblastoma (pRB) tumor suppressor, E2F1 activity is tightly controlled, as pRB binding represses E2F1-mediated transcription until phosphorylation releases E2F1 during the late G1 phase. E2F1 upregulates genes required for DNA replication, including those encoding cyclins, DNA polymerases, and dihydrofolate reductase. E2F1 exerts a dual role in cell fate by promoting apoptosis under stress conditions through both p53-dependent and independent mechanisms, involving transcriptional activation of pro-apoptotic genes such as APAF-1, p73, and caspases. E2F1 is phosphorylated and stabilized by ATM/ATR kinases in response to DNA damage, linking genotoxic stress signaling to apoptosis. Elevated E2F1 expression has been correlated with oncogenic transformation in multiple cancers, where its deregulation promotes uncontrolled proliferation and genomic instability. Moreover, aberrant E2F1 activity has been implicated in neuronal apoptosis, contributing to neurodegenerative disorders.

Usage Information

Application

WB, IP, IHC, IF

Dilution

WB	IHC	IF
1:100-1:1000	1:50-1:500	1:50-1:500

Reactivity

Human, Mouse, Rat

Source

Mouse Monoclonal Antibody

MW

60 kDa

Storage Buffer

PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage
(from the date of receipt)

-20°C (avoid freeze-thaw cycles), 2 years

Exprimental Methods

References

https://pubmed.ncbi.nlm.nih.gov/22180494/
https://pubmed.ncbi.nlm.nih.gov/32787501/

Application Data

WB

Validated by Selleck

Lane 1: Hela, Lane 2: CaCo-2, Lane 3: A431, Lane 4: MOLT-4